Halozyme EVP granted options and RSUs

HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions.

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS EVP David A. Ramsay reported a series of equity compensation transactions. On July 1, 2026 he received an option to buy 39,823 shares of common stock at $77.01 per share and a grant of 16,232 restricted stock units.

On June 30, 2026 10,000 restricted stock units vested and were settled in common shares, with 5,408 shares withheld by the company to cover tax obligations and 4,592 shares remaining directly owned. The filing shows routine grants, vesting, and tax withholding rather than open-market trading.

Insider Trade Summary

10,000 shares exercised/converted

Exercise 5 txns

Insider RAMSAY DAVID A

Role EVP, PRESIDENT, DRUG DELIVERY

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	16,232	$0.00	$0.00
Grant/Award	Option to Purchase Common Stock	39,823	$0.00	$0.00
Exercise	Restricted Stock Units	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	5,408	$78.27	$423K

Holdings After Transaction: Restricted Stock Units — 16,232 contracts (Direct); Option to Purchase Common Stock — 39,823 contracts (Direct); Common Stock — 4,592 shares (Direct)

Footnotes (4)

1. F1. The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
2. F2. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.
3. F3. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.
4. F4. This option vests one-fourth on such date and then 1/48th monthly thereafter.

Key Figures

Stock option grant: 39,823 shares at $77.01 RSU grant: 16,232 units RSU vesting: 10,000 units +3 more

6 metrics

Stock option grant 39,823 shares at $77.01 Option to purchase common stock granted July 1, 2026

RSU grant 16,232 units Restricted stock units granted July 1, 2026

RSU vesting 10,000 units Restricted stock units vested June 30, 2026

Tax withholding shares 5,408 shares at $78.27 Shares withheld to satisfy tax obligations June 30, 2026

Shares held after withholding 4,592 shares Common stock directly owned after June 30, 2026 tax withholding

Option expiration July 1, 2036 Expiration date of 39,823-share stock option

Key Terms

Restricted Stock Units, tax withholding obligations, vests one-fourth on the first anniversary, Exercise or conversion of derivative security, +1 more

5 terms

Restricted Stock Units financial

"This transaction represents the vesting and settlement of restricted stock units in shares of common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"represents the shares that were withheld by the issuer as payment for tax withholding obligations"

vests one-fourth on the first anniversary financial

"This award vests one-fourth on the first anniversary of the grant date"

Exercise or conversion of derivative security financial

"transaction code description: Exercise or conversion of derivative security"

one-year holding period financial

"The shares received upon vesting remain subject to a one-year holding period from the vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did HALO EVP David A. Ramsay receive in this Form 4?

David A. Ramsay received an option for 39,823 shares at $77.01 per share and a grant of 16,232 restricted stock units. These are compensation-related awards, not open-market stock purchases, and provide potential future ownership in Halozyme common stock.

How many Halozyme shares were involved in the June 30, 2026 RSU vesting for HALO EVP?

On June 30, 2026, 10,000 restricted stock units vested and settled into common shares. Of these, 5,408 shares were withheld to cover tax obligations, and 4,592 shares remained directly owned by David A. Ramsay after the tax withholding transaction.

Was there an open-market stock sale or purchase by HALO EVP David Ramsay?

The Form 4 shows no open-market buys or sells. Reported transactions are equity awards, option exercises, RSU vesting, and 5,408 shares withheld by Halozyme to pay tax obligations, which is not a discretionary market sale by the executive.

What are the vesting terms of the new Halozyme stock option granted to the EVP?

The new option for 39,823 shares at $77.01 vests one-fourth on the first anniversary of the grant date, then 1/48th monthly thereafter. This schedule gradually delivers exercisable options over several years, aligning part of compensation with longer-term company performance.

What are the vesting terms of the new restricted stock units granted to the HALO EVP?

The award of 16,232 restricted stock units vests one-fourth on the first anniversary of the grant date and one-fourth on each anniversary thereafter. This four-year vesting structure is designed to retain the executive and tie compensation to sustained service and company results.

How many Halozyme shares does the EVP hold directly after the tax withholding event?

Following the June 30, 2026 tax withholding event, David A. Ramsay directly held 4,592 shares of common stock from that specific RSU vesting. This figure reflects the shares remaining after 5,408 shares were withheld by Halozyme to satisfy tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAMSAY DAVID A

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, PRESIDENT, DRUG DELIVERY

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		M		10,000	A	$0	10,000	D
Common Stock	06/30/2026		F		5,408(1)	D	$78.27	4,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	06/30/2026		M			10,000	(2)	(2)	Common Stock	10,000	$0	0	D
Restricted Stock Units	$0	07/01/2026		A		16,232		07/01/2027(3)	(3)	Common Stock	16,232	$0	16,232	D
Option to Purchase Common Stock	$77.01	07/01/2026		A		39,823		07/01/2027(4)	07/01/2036	Common Stock	39,823	$0	39,823	D

Explanation of Responses:

1. The reported disposition of 5,408 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.

2. This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. The shares received upon vesting remain subject to a one-year holding period from the vesting date.

3. This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter.

4. This option vests one-fourth on such date and then 1/48th monthly thereafter.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)